TrialClinical and translational science2025

Japanese Phase 1 Study for Global Development of Anti-TL1A Antibody PF-06480605: A Randomized, Placebo-Controlled, Single-Ascending Dose Study.

Kei Fukuhara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.